Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences
暂无分享,去创建一个
E. Gamelin | M. Boisdron-Celle | E. Cvitkovic | S. Brienza | R. Delva | V. Guérin-Meyer | M. Craipeau
[1] S. Joel,et al. Lack of pharmacokinetic interaction between 5‐fluorouracil and oxaliplatin , 2004, Clinical pharmacology and therapeutics.
[2] E. Gamelin,et al. Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Caen,et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] J. Robert,et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Hiddemann,et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Gamelin,et al. A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites , 1997 .
[7] E. Gamelin,et al. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[8] J. Robert,et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] C. Tournigand,et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.
[10] F. Lévi,et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Gamelin,et al. Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.
[12] F. Demard,et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. , 1992, Cancer research.
[13] A. Reinberg,et al. A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.
[14] J. Willson,et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Robert B. Diasio,et al. Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.
[16] J G Fryer,et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Peters,et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.
[18] H. Pinedo,et al. Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F N Naguib,et al. Enzymes of uracil catabolism in normal and neoplastic human tissues. , 1985, Cancer research.
[20] R. Dedrick,et al. Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.
[21] J. Rosenfeld,et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. , 1978, British Journal of Cancer.
[22] W. Wolberg,et al. Pharmacokinetics of fluorouracil in humans. , 1978, Cancer research.
[23] F. Demard,et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer , 2004, Cancer Chemotherapy and Pharmacology.
[24] M. Ychou,et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] S. Iacobelli,et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.
[26] R. Diasio,et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.
[27] M. Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[28] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.